Phage therapy at a crossroads: global experts unite in Berlin for groundbreaking 2025 Congress

(Press-News.org) Berlin, Germany – April 7, 2025 — With antimicrobial resistance rising as one of the world's most pressing health threats, the 8th World Congress on Targeting Phage Therapy 2025 will bring together the global phage community to shape the future of infection control and microbiota modulation. Taking place on June 10–11, 2025, at the DoubleTree by Hilton Berlin Ku'damm, this landmark event will showcase cutting-edge research, real-world clinical insights, and groundbreaking applications of bacteriophage therapy across medicine, oncology, agriculture, and industry.

Strategic Importance

Phage therapy has entered a new era—transitioning from laboratory innovation to real-world implementation. This Congress will serve as a strategic forum to address the clinical, regulatory, and industrial challenges that must be overcome to bring phage-based solutions to the forefront of global health systems.
A roundtable titled "The Future of Phage Therapy in Europe: The Missing Link" will spotlight key regulatory gaps, scalability issues, and public-private collaboration models necessary to foster adoption and integration across sectors.

Visionary Keynotes from Clinical and Strategic Leaders

The Congress will open with a keynote address by Professor Robert T. Schooley (UC San Diego, USA) titled "Phage Therapy 2030: Getting from Here to There." As one of the leading figures in infectious disease and phage clinical trials, Prof. Schooley will present a roadmap for integrating phage therapy into mainstream medical practice within the next five years.

Following the keynote, Professor Christian Willy (Academic Hospital Bundeswehr Berlin, Germany) will take the stage with "Bacteriophage Therapy: A Renaissance – From Military Medicine to Civilian Healthcare." Drawing from his experience in both defense medicine and civilian healthcare systems, Prof. Willy will examine how phage therapy is evolving from battlefield necessity to an essential pillar of 21st-century infection management.

Elite Scientific and Clinical Program

The two-day program features a world-class lineup of speakers covering key domains:

Prof. Stan J.J. Brouns (TU Delft, Netherlands) – Phage defense systems and their role in therapeutic success. Prof. Dennis Sandris Nielsen (University of Copenhagen, Denmark) – The gut virome and phage communities in microbiota balance. Prof. Mikael Skurnik (University of Helsinki, Finland) – Yersinia phages and translational insights. Dr. Jumpei Fujiki (Rakuno Gakuen University, Japan) – Phage resistance in Pseudomonas infections. Dr. Jeremy Barr (Monash University, Australia) – Clinical translation and future challenges of phage therapy. Prof. Alberto Danielli & Dr. Alena Kaltenbrunner (University of Bologna, Italy) – Engineered phages in precision oncology. Prof. Christian Kühn (Hannover Medical School, Germany) – Use of phages in cardiothoracic surgical infections. Prof. Hidetomo Iwano (Rakuno Gakuen University, Japan) – First clinical phage trial in veterinary medicine in Japan. Dr. Sandra Sevilla (Spain) – Phages in broiler farming and food safety. Dr. Barbara Brenner (Germany) – Legal and ethical framework for phage therapy in Europe. Dr. Gail L. Stanley (Yale University, USA) – Inhaled bacteriophage therapy for multidrug-resistant Pseudomonas aeruginosa. Dr. Franklin Nobrega (University of Southampton, UK) – KlebPhaCol: Novel gut phage order associated with the human gut. Prof. Domenico Frezza (University of Roma Tor Vergata, Italy) – Optimizing phage-bacteria ratio in phage therapy. Prof. Loris Rizzello (University of Milan, Italy) – Endolysin B as a new approach in M. tuberculosis treatment. Dr. Marco Cafora (University of Milan, Italy) – Ex vivo pig lung as a new Cystic Fibrosis model for phage therapy application. Industry and Innovation Spotlight: Call for Startups and Companies

This year, the Congress invites biotech companies, pharmaceutical firms, and startups to actively participate and showcase their phage-based innovations, platforms, and technologies. Dedicated exhibition spaces, B2B networking zones, and pitch sessions will facilitate direct engagement between researchers, clinicians, industry leaders, and potential investors—accelerating the path from discovery to deployment. You can submit your innovations until May 2.

Practical Sessions and Workshops

In addition to scientific sessions, the event will include a hands-on workshop on GMP-compliant phage production, quality control, and commercialization—critical for those aiming to scale up phage-based therapeutics for human or industrial applications.

About Targeting Phage Therapy 2025

The World Congress on Targeting Phage Therapy is the leading international event dedicated to the advancement of bacteriophage science and application. It brings together multidisciplinary experts to foster innovation, combat antimicrobial resistance, and develop next-generation microbiome and precision medicine solutions.

Media Contact & Accreditation

Visit www.phagetherapy-site.com or email info@phagetherapy-site.com for press inquiries, speaker interviews, or exhibition opportunities.

 

END